Blood Eosinophil Count as a Predictor of Lung Function Decline in Healthy Individuals.

Lee, So-Hee; Ahn, Kyung-Min; Lee, Suh-Young; Kim, Sun-Sin; Park, Heung-Woo · J Allergy Clin Immunol Pract · 2021

prospective_cohort · Level II

Where this comes from

Abstract

Little is known about the effect of blood eosinophil count (BEC) on a decline in lung function in healthy individuals. Using a well-established health screening database, we assessed the associations between BEC and a decline in lung function, measured as the forced expiratory volume in 1 second (FEV<sub>1</sub>). Serial BEC and FEV<sub>1</sub> data were analyzed using linear mixed models adjusted for gender, height, and smoking status. The association between BEC consistency and a decline in FEV<sub>1</sub> was evaluated in subpopulation analyses. A total of 4634 individuals were enrolled. The mean number of health screenings was 7.49 over an average of 11.74 years of observation. A higher log2-transformed BEC was significantly associated with a greater decline in FEV<sub>1</sub> that was stronger in nonsmokers (P = 8.56 × 10<sup>-8</sup>) than in smokers (P = 1.52 × 10<sup>-3</sup>). In subpopulation analyses of 2018 individuals with consistent BECs, those with BECs consistently ≥100/μL (P = 4.58 × 10<sup>-6</sup>), ≥200/μL (P = 3.53 × 10<sup>-7</sup>), and ≥300/μL (P = 1.12 × 10<sup>-3</sup>) had a significantly higher dose-dependent FEV<sub>1</sub> decline than those with BECs consistently <100/μL. A BEC threshold of 100/μL in nonsmokers and 200/μL in smokers may predict an accelerated decline in FEV<sub>1</sub>. BEC is associated with a decline in FEV<sub>1</sub>, and a consistently high BEC is an independent risk factor for an accelerated decline in FEV<sub>1</sub>. These results suggest the use of the BEC to identify healthy individuals at high risk for developing chronic lung disease, which in turn may enable a tailored preventive strategy.

Medical subject headings